All In Biotech

NDA 207589 · Leo Pharma As

Enstilar

Betamethasone Dipropionate, Calcipotriene · Topical

Last checked: Nov 20, 2026Latest source record: Aug 6, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 16, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

127

30 Phase 3, 11 recruiting

FAERS reports

1,902

1,359 serious, 95 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 18, 2021.

Enstilar ® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older. Enstilar Foam is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis in patients 12 years and older. ( 1 )

Mechanism: Enstilar Foam combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis are unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ENSTILAR · BETAMETHASONE DIPROPIONATE 0.064%; CALCIPOTRIENE 0.005% · AEROSOL, FOAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • psoriasis398
  • drug ineffective181
  • diarrhoea138
  • pruritus132
  • pain111
  • headache109
  • fatigue92
  • arthralgia90
  • psoriatic arthropathy90
  • rash86
  • nausea82
  • dyspnoea77

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201011
201216
20141
20154
201661
2017100
2018160
2019239
2020279
2021219
2022198
2023272
2024149
2025116
202677

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Enstilar (Calcipotriene/Betamethasone)

2024 spending

$6.9M

Beneficiaries

1,839

4,017 claims

Per beneficiary

$3,770

$21.56 per unit

View as table
YearSpending
2020$6,732,316
2021$8,326,167
2022$8,316,305
2023$8,115,846
2024$6,933,006

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 225 on PubMed

Sponsor: Leo Pharma As

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.